Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pregabalin,Naproxen
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NDA Application of XG005 will Follows a Regulatory Pathway Bosed on FDA’s Feedback
Details : XG005 is a drug conjugate of naproxen and pregabalin which is being investigated for the management of acute pain.
Brand Name : XG005
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 22, 2020
Lead Product(s) : Pregabalin,Naproxen
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?